Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Authors
Moehler, MMahlberg, R
Heinemann, V
Obermannová, R
Kubala, E
Melichar, B
Weinmann, A
Scigalla, P
Tesařová, M
Janda, P
Hédouin-Biville, F
Mansoor, Was
Affiliation
Medizinische Klinik und Poliklinik, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, GermanyIssue Date
2016-06-02
Metadata
Show full item recordAbstract
This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS).Citation
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. 2016: Gastric CancerJournal
Gastric CancerDOI
10.1007/s10120-016-0618-0PubMed ID
27255289Type
ArticleLanguage
enISSN
1436-3305ae974a485f413a2113503eed53cd6c53
10.1007/s10120-016-0618-0
Scopus Count
Collections
Related articles
- Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
- Authors: Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB
- Issue date: 2012 Aug
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
- Authors: Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E
- Issue date: 2014 Aug
- S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies.
- Authors: Pfeiffer P, Qvortrup C, Krogh M, Schoennemann K, Vestermark LW, Jensen HA, Bjerregaard JK
- Issue date: 2017 Jan
- A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
- Authors: Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, Inokuchi Y, Tanabe S, Kumekawa Y, Koizumi W
- Issue date: 2017 Mar
- Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
- Authors: Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH
- Issue date: 2013 Nov